Treatment News : Worse Seroconversion Illness Linked to Faster AIDS Diagnosis

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » December 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


December 12, 2013

Worse Seroconversion Illness Linked to Faster AIDS Diagnosis

The severity of seroconversion illness in the six months following HIV acquisition is linked to a shorter time before the development of AIDS-related conditions, aidsmap reports. Publishing their findings in PLOS ONE, researchers from the international CASCADE collaboration studied a cohort of 1,108 HIV-positive individuals who had an identifiable, approximate seroconversion date.

The study defined severe seroconversion illness by the presence during primary HIV infection (PHI, the first six months after infection) of symptoms such as thrush in the mouth or throat, bronchitis, pneumonia or a low platelet count. Low CD4 measurements were additional markers.

There was available data on clinical symptom severity during PHI for 865 participants. Fifteen percent of them (127) had severe cases. Those with severe symptoms had a median AIDS-free survival period of 6.3 years, compared with 8.3 years for those who did not have severe symptoms.

A total of 443 participants had two CD4 counts available from PHI. Those who did not have a CD4 count below 350 had a median AIDS-free survival period of 8.1 years, compared with 5.4 years for those with one count below 350 and 3.9 years for those with two counts below 350. Those who had no CD4 measurements below 500 had a 7.5 year median AIDS-free survival period, compared with a respective 6.7 and 4.8 years for those with one or two tests below 500.

Those who had severe seroconversion illness symptoms and a CD4 count below 500 had twice the overall risk of AIDS-related illness or death when compared with those who only had severe symptoms.

The investigators concluded that those who are newly infected with HIV and who have at least one CD4 measurement below 350 or severe seroconversion illness symptoms would likely benefit from early antiretroviral treatment as well as close clinical monitoring. However, they stated that more research is needed to establish the benefit of early treatment during PHI.

To read the aidsmap story, click here.

To read the study abstract, click here.

Search: Seroconversion illness, primary HIV infection, PHI, CASCADE collaboration, PLOS One, AIDS-defining illnesses, HIV, CD4 count.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.